AI & Technology's Role in Pharmacovigilance: Insights from Eric Prugh
AI & Technology's Revolution in Pharmacovigilance
As artificial intelligence (AI) continues to evolve, its role in **pharmacovigilance** is becoming increasingly significant. AI & technology are tackling the long-standing issues of inconsistent adverse event reporting, a challenge that has plagued the industry for years. Eric Prugh, Chief Product Officer at Authenticx, sheds light on how these innovations are reshaping the landscape of **clinical trials & development**.
The Importance of Data Management
With advancements in **data management**, the potential to streamline reporting processes has never been greater. By using AI algorithms, organizations can enhance the accuracy of data and ensure that adverse events are reported consistently and effectively. This is particularly crucial in **contract sales & marketing**, where timely and precise information is vital.
Advancements in the Clinical Development Landscape
As we move forward, the integration of AI & technology in **clinical development** presents numerous opportunities for improvement. The conversation initiated by Eric Prugh emphasizes the need for ongoing investment in these technologies to overcome regulatory hurdles and market challenges.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.